Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-07

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open-label, single ascending dose escalation followed by a multiple administration dose at the maximal suitable dose (MSD). The investigational Medicinal Product (IMP) is given as an add-on therapy.

Talineuren consists of GM1 (monosialotetrahexosylganglioside), the pharmacologically active ingredient, associated with a proprietary lipid formulation assembled as liposomes.

The primary objective is to demonstrate the safety of TLN administration intravenously in Parkinson patients.

Secondary objectives are the determination of the maximal suitable dose based on the safety profile and preliminary efficacy, as well as the determination of the pharmacokinetics (PK) profile.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

NCT06431971

Parkinson Disease

NOT_YET_RECRUITING PHASE2

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

NCT04056689

Parkinson's Disease

COMPLETED PHASE1

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

NCT07216066

Parkinsons Disease

RECRUITING PHASE1

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

NCT02337738

Parkinson's Disease

COMPLETED PHASE2/PHASE3

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

NCT03624920

Parkinson Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ganglioside lipid GM1 has been described in the literature as a neuroprotective agent.

Several clinical studies have shown that GM1 improves the condition of Parkinson's disease patients.

Talineuren consists of the pharmacologically active ingredient GM1, associated with a proprietary lipid formulation assembled as liposomes. Talineuren has been developed to improve the delivery and bioavailability of GM1.

The primary objective of this trial is to demonstrate the feasibility and safety of intravenous Talineuren administration in Parkinson's disease patients.

The secondary objectives are:

* The determination of the recommended phase 2 dose based on the safety profile and preliminary efficacy.
* The determination of the pharmacokinetics (PK) profile.

This trial aims to investigate the safety of the novel formulation of GM1, Talineuren.

To that extent a three-part trial was designed: Part 1- Dose escalation Part 2- Dose consolidation Part 3- Dose consolidation with intrapatient dosing

Part 1- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren formulated GM1 in 3 patients. Optional treatment prolongations for 8 weeks (Amendment 1), 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).

Part 2- multiple dosing of Talineuren over 8 weeks in 9 patients to validate the safety profile of the maximum suitable dose. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).

Part 3- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren followed by multiple doses of 720mg Talineuren for up to 8 months in 10 patients (Amendment 3).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Part 1: dose escalation phase, 3 patients with Parkinson's disease, (2 cohorts as in 1+2 patients, sequential inclusion between the first and 2nd patient)

Part 2: repeated dose administration phase, 9 patients with Parkinson's disease (1 cohort)

Part 3: Dose consolidation with intrapatient dosing, 10 patients with Parkinson's disease (1 cohort)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Talineuren dose escalation

14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).

Group Type EXPERIMENTAL

Talineuren

Intervention Type DRUG

Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Talineuren repeated dose

8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).

Group Type EXPERIMENTAL

Talineuren

Intervention Type DRUG

Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Talineuren dose consolidation with intrapatient dosing

8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).

Group Type EXPERIMENTAL

Talineuren

Intervention Type DRUG

Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Talineuren

Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

liposomal GM1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent as documented by signature.
* Confirmed Parkinson's disease according to British brain bank criteria.
* Hoehn and Yahr Stage 0 - 2.5 on medication.
* Stable on PD treatment for a month at least.
* Absence of dementia confirmed by cognitive testing (MoCA \>25).

Exclusion Criteria

* Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to class of drugs or the investigational product.
* Women who are pregnant or breast feeding, or planning to become pregnant during the course of the trial or in the 3 months following the trial.
* Lack of safe contraception in women with childbearing potential
* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc) that is not under stable control.
* Subject has an atypical parkinsonian syndrome or secondary parkinsonism.
* Patients with comorbidity that may interfere with the course of the trial.

Minimum Eligible Age

30 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No